---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-038258"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2026-04-01T23:59:59+00:00"
generated_at: "2026-05-15T07:59:51.939838+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aprea Therapeutics closes oversubscribed $30M private placement to fund APR-1051 development

## Summary
- Closed oversubscribed $30M private placement on March 31, 2026; proceeds for R&D and general corporate.
- Proceeds to accelerate APR-1051 development, targeting uterine serous carcinoma and platinum-resistant ovarian cancer with 50+ patients.
- Offering led by Soleus Capital; included pre-funded warrants at ~$0.807/sh and warrants at $0.683/sh, expiring Dec 2029.

## SEC filing metadata
- accession: 0001104659-26-038258
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2026-04-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000110465926038258/0001104659-26-038258-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000110465926038258/apre-20260401x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-038258
- JSON: https://secwatch.observer/filing/0001104659-26-038258.json
- Plain text: https://secwatch.observer/filing/0001104659-26-038258.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.